Moderna’s Big Biotech Repricing
Moderna and Merck reported positive Phase 3 results from the INTerpath-001 trial evaluating intismeran autogene with KEYTRUDA in patients with completely resected melanoma. The trial met its primary recurrence-free survival endpoint and a key secondary distant-metastasis-free survival endpoint.
The result is an important milestone for personalized mRNA cancer therapy, but it’s worth keeping the distinction clear: the treatment remains investigational and regulatory steps are still ahead. The market reaction around MRNA shows how quickly biotech valuations can change when meaningful clinical data arrives. BingX is one platform where the MRNA market move can be followed.
Moderna and Merck reported positive Phase 3 results from the INTerpath-001 trial evaluating intismeran autogene with KEYTRUDA in patients with completely resected melanoma. The trial met its primary recurrence-free survival endpoint and a key secondary distant-metastasis-free survival endpoint.
The result is an important milestone for personalized mRNA cancer therapy, but it’s worth keeping the distinction clear: the treatment remains investigational and regulatory steps are still ahead. The market reaction around MRNA shows how quickly biotech valuations can change when meaningful clinical data arrives. BingX is one platform where the MRNA market move can be followed.